Skip to main content
19 search results for:

Insulin degludec/Liraglutide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-14-2020 | Tirzepatide | At a glance | Article
    Updated April 2023

    A quick guide to the SURPASS and SURMOUNT trials

    Phase 3 and 4 trials of tirzepatide in type 2 diabetes and obesity

    Related news stories:  Tirzepatide has efficacy edge over semaglutide in SURPASS-2 Mechanisms underlying tirzepatide efficacy revealed SURPASS-3: Published Trial population: People taking metformin with/without an SGLT2 inhibitor Comparator treatment: Insulin degludec NCT03882970 In this trial, the investigators  compared the efficacy of weekly tirzepatide (5, 10, and 15 mg) with daily insulin degludec in people with poorly controlled blood glucose despite stable treatment with metformin with or without an SGLT (sodium-glucose cotransporter)2 inhibitor.

  2. 06-28-2017 | Topic page

    Insulin degludec_Liraglutide(1)

  3. 02-20-2019 | Insulin degludec/Liraglutide | News | Article

    Support for add-on IDegLira in SGLT2 inhibitor-treated type 2 diabetes

    Findings from the DUAL IX trial suggest that the addition of insulin degludec/liraglutide to SGLT2 inhibitor therapy results in better glycemic control than add-on insulin glargine among insulin-naïve patients with uncontrolled type 2 diabetes.

  4. 06-09-2019 | Insulin degludec/Liraglutide | ADA 2019 | Article

    IDegLira delays need for treatment intensification over glargine

    Patients with type 2 diabetes last for longer before needing treatment intensification if they are treated with fixed-ratio combination insulin degludec and liraglutide rather than insulin glargine 100 U/mL, show the DUAL VIII findings.

  5. 06-11-2017 | Insulin degludec/Liraglutide | News | Article

    Single insulin-liraglutide injection as good as basal-bolus insulin in type 2 diabetes

    Research shows that a fixed-dose combination of insulin degludec and liraglutide is as effective as a basal–bolus insulin regimen in insulin-dependent patients with type 2 diabetes, and requires just one daily injection.

  6. 12-15-2017 | Insulin degludec/Liraglutide | News | Article

    Real-world data confirm benefits of IDegLira

    IDegLira, which combines the basal insulin degludec with the glucagon-like peptide-1 receptor agonist liraglutide, improves glycemic control within 6 months of initiation irrespective of previous therapy, real-world study data show.

  7. 04-23-2021 | Insulin | News | Article

    Pragmatic trial challenges ‘dogma’ of basal–bolus insulin for advanced type 2 diabetes

    Combining a GLP-1 receptor agonist or SGLT2 inhibitor with basal insulin allows people with type 2 diabetes on a basal–bolus regimen to drop the prandial insulin, shows the pragmatic BEYOND trial.

  8. 09-21-2017 | Type 2 diabetes | EASD 2017 | Article

    Novel compounds show promise for type 2 diabetes

    In the DUAL II study, patients treated with insulin degludec/liraglutide for 26 weeks had a significantly greater reduction in systolic blood pressure than those who were treated with insulin degludec alone (5.4 vs 1.7 mmHg), in addition to significantly greater weight loss (2.7 vs 0.0 kg) and lower levels of total and LDL cholesterol.

  9. 09-20-2017 | Hypoglycemia | EASD 2017 | Article

    Hypoglycemia: Risk factors and Ramadan

    Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

  10. 10-23-2017 | Cardiovascular disorders | Editorial | Article

    Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

    Classification of GLP-1 RAs GLP-1 RA monotherapy Short acting Exenatide Lixisenatide Intermediate acting Liraglutide Long acting Dulaglutide Once-weekly exenatide GLP-1 RA + insulin coformulation Lixisenatide + glargine Liraglutide + degludec GLP-1 RA=glucagon-like peptide-1 receptor agonist Cardiovascular outcome trials As a class, GLP-1 RAs possess multiple pleiotropic effects which offer distinct CV advantages.

  11. 03-24-2018 | Insulin | Review | Article

    Basal insulin intensification in patients with type 2 diabetes: A review

    Meece J. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0395-3

  12. 08-18-2017 | Insulin | Review | Article

    New basal insulins: A clinical perspective of their use in the treatment of type 2 diabetes and novel treatment options beyond basal insulin

    The purpose of this review was to review advances in basal insulin formulations and new treatment options for patients with type 2 diabetes not

  13. 12-19-2016 | Editorial | Article

    Progress in diabetes care: looking back at 2016

    The year has ended with icing on the cake, as DEVOTE has announced its top line results, proving the cardiovascular safety of the ultra-long acting insulin analogue degludec in a high risk population.

  14. 10-23-2017 | Insulin | Review | Article

    Insulin and its cardiovascular effects: What is the current evidence?

    In this article, we examine the nature of the complex relationship between insulin and cardiovascular disease.

  15. 08-23-2017 | Obesity | Review | Article

    Weight management in patients with type 1 diabetes and obesity

    Mottalib A et al. Curr Diab Rep 2017; 17: 92. doi: 10.1007/s11892-017-0918-8

  16. 03-27-2017 | Insulin degludec/Liraglutide | Article

    IDegLira versus insulin glargine U100: A long-term cost-effectiveness analysis in the US setting

    Hunt B et al. Diabetes Ther 2017; 8: 531–544. doi: 10.1007/s13300-017-0251-x

  17. 10-23-2017 | Cardiovascular disorders | Review | Article

    Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

    Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

  18. 05-04-2017 | Insulin degludec/Liraglutide | Article

    Evaluation of the short-term cost-effectiveness of IDegLira versus continued up-titration of insulin glargine U100 in patients with type 2 diabetes in the USA

    Hunt B et al. Adv Ther 2017; 34: 954–965. doi: 10.1007/s12325-017-0502-2

  19. 10-11-2017 | Cardiovascular disorders | Review | Article

    Updates on cardiovascular outcome trials in diabetes

    Schnell O et al. Cardiovasc Diabetol 2017; 16: 128. doi: 10.1186/s12933-017-0610-y

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.